Literature DB >> 2938016

Requirement for c-ras proteins during viral oncogene transformation.

M R Smith, S J DeGudicibus, D W Stacey.   

Abstract

Many retroviral oncogenes have been classified into one of several categories based on structure, enzymology and cellular localization. These genes originated from host cells and are probably derived from genes normally involved in the control of cell proliferation. The cellular counterparts of three oncogenes have been identified as a growth factor or growth factor receptor; related oncogenes include receptor-like membrane proteins which often express tyrosine kinase activity. These growth factor-related oncogenes are structurally and biochemically distinct from the membrane-associated ras gene family, which bind and hydrolyse GTP. Oncogenes localized primarily in the cytoplasm which probably have serine kinase activity, have also been identified. Although the structure and biochemistry of many oncogenes have been extensively studied, relatively little is known about the functional relationships of oncogene proteins within the cell. An opportunity to study such interaction is provided by the identification of a monoclonal antibody that neutralizes cellular ras proteins when microinjected into cells. It has been shown previously that the injected antibody inhibits the initiation of S-phase in NIH 3T3 cells. In the present study we injected this monoclonal antibody into NIH 3T3 cells transformed by a variety of oncogenes. The results show that transformation by three growth factor receptor-like oncogenes depends on c-ras proteins, while transformation by two cytoplasmic oncogenes appears to be independent of c-ras protein.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2938016      PMCID: PMC7095476          DOI: 10.1038/320540a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  26 in total

1.  Identification of a transformation-specific antigen induced by an avian sarcoma virus.

Authors:  J S Brugge; R L Erikson
Journal:  Nature       Date:  1977-09-22       Impact factor: 49.962

Review 2.  Viral oncogenes.

Authors:  J M Bishop
Journal:  Cell       Date:  1985-08       Impact factor: 41.582

3.  Reversal of transformed phenotype by monoclonal antibodies against Ha-ras p21 proteins.

Authors:  H F Kung; M R Smith; E Bekesi; V Manne; D W Stacey
Journal:  Exp Cell Res       Date:  1986-02       Impact factor: 3.905

4.  Further characterization of the P85gag-mos -associated protein kinase activity.

Authors:  W S Kloetzer; S A Maxwell; R B Arlinghaus
Journal:  Virology       Date:  1984-10-15       Impact factor: 3.616

5.  Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells.

Authors:  L S Mulcahy; M R Smith; D W Stacey
Journal:  Nature       Date:  1985 Jan 17-23       Impact factor: 49.962

6.  DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells.

Authors:  M Wigler; A Pellicer; S Silverstein; R Axel; G Urlaub; L Chasin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

7.  Comparative biochemical properties of normal and activated human ras p21 protein.

Authors:  J P McGrath; D J Capon; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

8.  Generation of oncogenic mouse type C viruses: in vitro selection of carcinoma-inducing variants.

Authors:  U R Rapp; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

9.  The ras oncogene product p21 is not a regulatory component of adenylate cyclase.

Authors:  S K Beckner; S Hattori; T Y Shih
Journal:  Nature       Date:  1985 Sep 5-11       Impact factor: 49.962

10.  Recombinant bacteriophages containing the integrated transforming provirus of Gardner--Arnstein feline sarcoma virus.

Authors:  L A Fedele; J Even; C F Garon; L Donner; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

View more
  170 in total

1.  Non-transcriptional action of oestradiol and progestin triggers DNA synthesis.

Authors:  G Castoria; M V Barone; M Di Domenico; A Bilancio; D Ametrano; A Migliaccio; F Auricchio
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

2.  v-Src generates a p53-independent apoptotic signal.

Authors:  B L Webb; E Jimenez; G S Martin
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  p21ras activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21ras GTPase-activating protein.

Authors:  V Duronio; M J Welham; S Abraham; P Dryden; J W Schrader
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

4.  Regulation of collagen I gene expression by ras.

Authors:  J L Slack; M I Parker; V R Robinson; P Bornstein
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

5.  Persistence of Ha-ras-induced metastatic potential of SP1 mouse mammary tumors despite loss of the Ha-ras shuttle vector.

Authors:  B Schlatter; C G Waghorne
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

6.  Isolation of rsp-1, a novel cDNA capable of suppressing v-Ras transformation.

Authors:  M L Cutler; R H Bassin; L Zanoni; N Talbot
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

Review 7.  Molecular signal integration. Interplay between serine, threonine, and tyrosine phosphorylation.

Authors:  J Posada; J A Cooper
Journal:  Mol Biol Cell       Date:  1992-06       Impact factor: 4.138

8.  Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras.

Authors:  D W Stacey; L A Feig; J B Gibbs
Journal:  Mol Cell Biol       Date:  1991-08       Impact factor: 4.272

9.  Inhibition of v-src-induced transformation by a GTPase-activating protein.

Authors:  M Nori; U S Vogel; J B Gibbs; M J Weber
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

Review 10.  Signal transduction by Ras-like GTPases: a potential target for anticancer drugs.

Authors:  M Spaargaren; J R Bischoff; F McCormick
Journal:  Gene Expr       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.